Pfizer Unveils $214 Million Biotech Facility in Sweden

August 27, 2009

Pharmaceutical giant Pfizer, Inc., (New York, NY) has opened a new 64,600-square-foot biotech plant in Strangnas, Sweden.

Pharmaceutical giant Pfizer, Inc., (New York, NY) has opened a new 64,600-square-foot biotech plant in Strängnäs, Sweden. The new facility is expected to be commercially operational in 2011.

Products made at the $214-million plant will include Pfizer's human growth hormone, or Genotropin, along with the drug Somavert for acromegaly, and drugs based on E. coli and yeast.

The new plant will be connected to the existing facility in Strängnäs, which will facilitate the flow of material as well as personnel. An older part of the Strängnäs facility will close when the new facility is fully approved, said a Pfizer representative.

Forbes coverage

Speed and Efficiency in Designing and Building a Monoclonal Antibodies Pilot Plant-A close-up look at Pfizer's biotherapeutics plant under development in Shanbally, Ireland